Progressive Pleural Effusion as an Immune-Related Adverse Event in NSCLC: A Case Report

por Shen, Chia-I, Yeh, Yi-Chen, Chiu, Chao-Hua
Publicado 2021

Pathological complete response after afatinib treatment of stage IV oligometastatic adenocarcinoma of the lung: the role of pulmonary surgery

por Tsai, Ping-Chung, Yeh, Yi-Chen, Huang, Chien-Sheng, Chiu, Chao-Hua
Publicado 2019

Salvage surgery after definitive chemoradiotherapy through VATS for an initial unresectable locally advanced lung cancer: an alternative consolidative modality to radiotherapy?

por Yu, Hsuan-Hsuan, Chen, Yi-Wei, Yeh, Yi-Chen, Huang, Chien-Sheng, Chiu, Chao-Hua
Publicado 2021

Cytology–Based Specimen Triage for Epidermal Growth Factor Receptor Mutation Testing of Malignant Pleural Effusions in Non–Small Cell Lung Cancer

por Chiang, Chi-Lu, Shen, Chia-I, Huang, Hsu-Ching, Chang, Han-Jhih, Huang, Yu-Ting, Chiu, Chao-Hua
Publicado 2022

Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Tr...

por Ho, Hsiang-Ling, Wang, Fang-Yu, Chiang, Chi-Lu, Tsai, Chun-Ming, Chiu, Chao-Hua, Chou, Teh-Ying
Publicado 2022

MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma

por Chiu, Chao-Hua, Ho, Hsiang-Ling, Doong, Howard, Yeh, Yi-Chen, Chen, Mei-Yu, Chou, Teh-Ying, Tsai, Chun-Ming
Publicado 2015

Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer

por Shen, Chia-I, Chiang, Chi-Lu, Shiao, Tsu-Hui, Luo, Yung-Hung, Chao, Heng-Sheng, Huang, Hsu-Ching, Chiu, Chao-Hua
Publicado 2022

Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer

por Shen, Chia-I, Chao, Heng-Sheng, Shiao, Tsu-Hui, Chiang, Chi-Lu, Huang, Hsu-Ching, Luo, Yung-Hung, Chiu, Chao-Hua, Chen, Yuh-Min
Publicado 2021

Reduced FEV(1) as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors

por Shen, Yi-Luen, Shen, Chia-I, Chiang, Chi-Lu, Huang, Hsu-Ching, Chou, Kun-Ta, Chiu, Chao-Hua, Chen, Yuh-Min, Luo, Yung-Hung
Publicado 2022

Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy

por Chiang, Chi-Lu, Wang, Lei-Chi, Ho, Hsiang-Ling, Tsai, Chun-Ming, Yeh, Yi-Chen, Hsu, Wen-Hu, Chou, Teh-Ying, Chiu, Chao-Hua, Wu, Yu-Chung
Publicado 2017

Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell‐free DNA from non‐small‐cell lung cancer patients with leptomeningeal metastases

por Chiang, Chi‐Lu, Ho, Hsiang‐Ling, Yeh, Yi‐Chen, Lee, Cheng‐Chia, Huang, Hsu‐Ching, Shen, Chia‐I, Luo, Yung‐Hung, Chen, Yuh‐Min, Chiu, Chao‐Hua, Chou, Teh‐Ying
Publicado 2023

Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer

por Ho, Hsiang-Ling, Jiang, Yuqiu, Chiang, Chi-Lu, Karwowska, Sylwia, Yerram, Ranga, Sharma, Keerti, Scudder, Sidney, Chiu, Chao-Hua, Tsai, Chun-Ming, Palma, John F., Sharma, Abha, Chou, Teh-Ying
Publicado 2022

Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the R...

por Chiu, Chao-Hua, Lin, Meng-Chih, Wei, Yu-Feng, Chang, Gee-Chen, Su, Wu-Chou, Hsia, Te-Chun, Su, Jian, Wang, Anne Kuei-Fang, Jen, Min-Hua, Puri, Tarun, Shih, Jin-Yuan
Publicado 2023

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

por Nishio, Makoto, Seto, Takashi, Reck, Martin, Garon, Edward B., Chiu, Chao‐Hua, Yoh, Kiyotaka, Imamura, Fumio, Park, Keunchil, Shih, Jin‐Yuan, Visseren‐Grul, Carla, Frimodt‐Moller, Bente, Zimmermann, Annamaria, Homma, Gosuke, Enatsu, Sotaro, Nakagawa, Kazuhiko
Publicado 2020

Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer

por Hung, Hsiu-Ying, Tseng, Yen-Han, Chao, Heng-Sheng, Chiu, Chao-Hua, Hsu, Wen-Hu, Hsu, Han-Shui, Wu, Yu-Chung, Chou, Teh-Ying, Chen, Chun-Ku, Lan, Keng-Li, Chen, Yi-Wei, Wu, Yuan-Hung, Chen, Yuh-Min
Publicado 2020

Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell‐derived organoids

por Wu, Yuan‐Hung, Chao, Heng‐sheng, Chiang, Chi‐Lu, Luo, Yung‐Hung, Chiu, Chao‐Hua, Yen, Sang‐Hue, Liu, Chun‐Yu, Chiou, Jeng‐Fong, Burnouf, Thierry, Chen, Yin‐Ju, Wang, Peng‐Yuan, Chao, Tsu‐Yi, Hsu, Shih‐Ming, Lu, Long‐Sheng
Publicado 2023

Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a mul...

por Yang, James Chih-Hsin, Su, Wu-Chou, Chiu, Chao-Hua, Shiah, Her-Shyong, Lee, Kang-Yun, Hsia, Te-Chun, Uno, Makiko, Crawford, Nigel, Terakawa, Hiroshi, Chen, Wen-Chi, Takayama, Gensuke, Hsu, Ching, Hong, Ying, Saintilien, Carline, McGill, Joseph, Chang, Gee-Chen
Publicado 2023

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

por Drilon, Alexander, Chiu, Chao-Hua, Fan, Yun, Cho, Byoung Chul, Lu, Shun, Ahn, Myung-Ju, Krebs, Matthew G., Liu, Stephen V., John, Thomas, Otterson, Gregory A., Tan, Daniel S.W., Patil, Tejas, Dziadziuszko, Rafal, Massarelli, Erminia, Seto, Takashi, Doebele, Robert C., Pitcher, Bethany, Kurtsikidze, Nino, Heinzmann, Sebastian, Siena, Salvatore
Publicado 2022

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

por Dziadziuszko, Rafal, Krebs, Matthew G., De Braud, Filippo, Siena, Salvatore, Drilon, Alexander, Doebele, Robert C., Patel, Manish R., Cho, Byoung Chul, Liu, Stephen V., Ahn, Myung-Ju, Chiu, Chao-Hua, Farago, Anna F., Lin, Chia-Chi, Karapetis, Christos S., Li, Yu-Chung, Day, Bann-mo, Chen, David, Wilson, Timothy R., Barlesi, Fabrice
Publicado 2021

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

por Zhou, Qing, Soo, Ross A., Chang, Gee-Chen, Chiu, Chao-Hua, Hayashi, Hidetoshi, Kim, Sang-We, Teraoka, Shunsuke, Goto, Yasushi, Zhou, Jianying, Ho-Fun Lee, Victor, Kim, Dong-Wan, Han, Baohui, Chung Man Ho, James, Lin, Chia-Chi, Lu, Shun, Polli, Anna, Calella, Anna Maria, Martini, Jean-François, Wong, Chew Hooi, Mok, Tony, Kim, Hye Ryun, Wu, Yi-Long
Publicado 2023